Product Launch

    Eli Lilly and Company

Lilly ICOS LLC (NYSE:LLY)(Nasdaq:ICOS) today has received the
approval letter for Cialis(R) from the Food and Drug Administration.
Further information will be forthcoming from Lilly ICOS.

About Lilly ICOS LLC

Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli
Lilly and Company, was formed to develop and market Cialis.
Lilly, a leading innovation-driven corporation, is developing a
growing portfolio of first-in-class and best-in-class pharmaceutical
products by applying the latest research from its own worldwide
laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides
answers - through medicines and information - for some of the world's
most urgent medical needs. Additional information about Lilly is
available at www.lilly.com.

ICOS Corporation is a product-driven company that has expertise in
both protein-based and small molecule therapeutics. ICOS combines its
capabilities in molecular, cellular and structural biology, high
throughput drug screening, medicinal chemistry and gene expression
profiling to develop highly innovative products expected to have
significant commercial potential. ICOS applies its integrated approach
to erectile dysfunction and other urologic disorders, sepsis and
inflammatory diseases. ICOS' strategy targets multiple therapeutic
areas with drugs that act through distinct molecular mechanisms,
increasing ICOS' opportunities to market breakthrough products.

Certain of the matters discussed herein with respect to clinical
studies and commercial plans for ICOS and Lilly's products may
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements are based on current expectations, estimates and
projections about the industry, management beliefs and certain
assumptions made by management. Investors are cautioned that matters
subject to forward-looking statements involve risks and uncertainties,
including economic, competitive, governmental, technological and other
factors discussed in the two companies' respective filings with the
Securities and Exchange Commission, which may affect the business and
prospects of the two companies. More specifically, there can be no
assurance that this product will receive additional regulatory
approvals as expected or achieve commercial success or that competing
products will not pre-empt any market opportunity that might exist for
the product. The companies undertake no duty to update forward-looking
statements.